Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations.
Muchmore
Douglas B
DB
Halozyme Therapeutics, Inc, San Diego, California, USA. dmuchmore@halozyme.com
Vaughn
Daniel E
DE
D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004435:Eating / Q000502:physiology*; D005818:Genetic Engineering; D015309:Glucose Clamp Technique / Q000379:methods; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000235:genetics / Q000627:therapeutic use*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061267:Insulin Aspart; D061268:Insulin Lispro; D007408:Intestinal Absorption / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro; D011994:Recombinant Proteins; D061267:Insulin Aspart; D006821:Hyaluronoglucosaminidase